Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,645,815

« Back to Dashboard
Patent 5,645,815 protects ACUTECT and is included in one NDA.

This patent has two hundred and forty-five patent family members in twenty-five countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 5,645,815

Title: Radiolabled compounds for thrombus imaging
Abstract:This invention relates to radiolabeled scintigraphic imaging agents, and methods and reagents for producing such agents. Specifically, the invention relates to specific binding compounds, including peptides, that bind to a platelet receptor that is the platelet GPIIb/IIIa receptor, methods and kits for making such compounds, and methods for using such compounds labeled with technetium-99m via a covalently-linked radiolabel-binding moiety to image thrombi in a mammalian body.
Inventor(s): Dean; Richard T. (Bedford, NH), Lister-James; John (Bedford, NH), Civitello; Edgar R. (Bradford, NH)
Assignee: Diatide, Inc. (Londonderry, NH)
Application Number:08/439,905
Patent Claim Types:
see list of patent claims
Compound; Composition; Device; Use;
Patent PDF download available with subscription

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cis Bio Intl Sa
ACUTECT
technetium tc-99m apcitide
INJECTABLE;INJECTION020887-001Sep 14, 1998DISCNNo5,645,815<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: 5,645,815

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
5,645,815
ACUTECT
July 08, 2009

Non-Orange Book Patents for Patent: 5,645,815

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,811,394 Technetium-99m labeled polypeptides for imaging<disabled in preview>
5,932,189 Cyclic peptide somatostatin analogs<disabled in preview>
5,681,541 Technetium-99m labeled radiopharmaceutical kit for imaging<disabled in preview>
5,993,775 Radioactively labeled peptides comprising a single thiol moiety<disabled in preview>
5,843,401 Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,645,815

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
JapanH09512555Dec 16, 1997
Spain2204954May 01, 2004
European Patent Office0614379Feb 13, 2002
Austria329624Jul 15, 2006
Norway974494Sep 29, 1997
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc